1. Hedegaard, H, Miniño, AM, Warner, M. Drug overdose deaths in the United States, 1999–2019. NCHS data brief, no 394. Hyattsville, MD: National Center for Health Statistics, 2020. www.cdc.gov/nchs/data/databriefs/db394-H.pdf
Google Scholar2. Mattson, CL, Tanz, LJ, Quinn, K, et al. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. MMWR Morb Mortal Wkly Rep 2021; 70: 202–207.
Google Scholar | Crossref | Medline3. Substance Abuse and Mental Health Services Administration . Public online data analysis system (PDAS). National Survey on Drug Use and Health: Concatenated Public Use File (2002 to 2019), https://pdas.samhsa.gov/#/survey/NSDUH-2002-2019-DS0001/crosstab/?results_received=true (accessed 10 August 2021).
Google Scholar4. Center for Behavioral Health Statistics and Quality . Results from the 2019 national survey on drug use and health: detailed tables. Rockville, MD: SAMHSA, 2019. www.samhsa.gov/data/sites/default/files/reports/rpt29394/NSDUHDetailedTabs2019/NSDUHDetTabsSec t1pe2019.htm
Google Scholar5. U.S. Department of Labor, Bureau of Labor Statistics . News release: national census of fatal occupational injuries in 2019. USDL-20-2265. Washington, DC: U.S. Department of Labor, Bureau of Labor Statistics, 16 December 2020. www.bls.gov/news.release/pdf/cfoi.pdf
Google Scholar6. Morano, LH, Steege, AL, Luckhaupt, SE. Occupational patterns in unintentional and undetermined drug-involved and opioid-involved overdose deaths—United States, 2007–2012. MMWR Morb Mortal Wkly Rep 2018; 67: 925–930.
Google Scholar | Crossref | Medline7. Kowalski-McGraw, M, Green-McKenzie, J, Pandalai, SP, et al. Characterizing the interrelationships of prescription opioid and benzodiazepine drugs with worker health and workplace hazards. J Occup Environ Med 2017; 59: 1114–1126.
Google Scholar | Crossref | Medline8. Choi, B. Opioid use disorder, job strain, and high physical job demands in US workers. Int Arch Occup Environ Health 2020; 93: 577–588.
Google Scholar | Crossref | Medline9. Drug Enforcement Administration . 2017 national drug threat assessment summary. Washington, DC: US Department of Justice, Drug Enforcement Administration, 2017. www.dea.gov/sites/default/files/2018-07/DIR-040-17_2017-NDTA.pdf
Google Scholar10. Osborne, J, Chosewood, C, Howard, J. The COVID-19 pandemic and the opioid overdose epidemic: a perfect storm for workers? https://blogs.cdc.gov/niosh-science-blog/2020/09/14/covid-19-and-oud/ (14 September 2020, accessed 10 August 2021).
Google Scholar11. American Medical Association . Issue brief: reports of increases in opioid- and other drug-related overdose and other concerns during COVID pandemic, www.ama-assn.org/system/files/2020-12/issue-brief-increases-in-opioid-related-overdose.pdf (accessed 10 August 2021).
Google Scholar12. Kuhl, E. SAMHSA disaster helpline sees increase in COVID-19 related outreach. Psychiatric News. https://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2020.5b29
Google Scholar13. Davis, CS, Samuels, EA. Opioid policy changes during the COVID-19 pandemic—and beyond. J Addict Med 2020; 14: e4–5. DOI: 10.1097/ADM.0000000000000679.
Google Scholar14. D’Onofrio, G, Venkatesh, A, Hawk, K. The adverse impact of Covid-19 on individuals with OUD highlights the urgent need for reform to leverage emergency department–based treatment. N Engl J Med Catal 2020; 10: 1056. DOI: 10.1056/CAT.20.0190. https://catalyst.nejm.org/doi/full/10.1056/CAT.20.0190
Google Scholar15. Jenkins, WD, Bolinski, R, Bresett, J, et al. COVID-19 during the opioid epidemic—exacerbation of stigma and vulnerabilities. J Rural Health 2020; 37: 172–174.
Google Scholar | Crossref | Medline16. National Institute on Drug Abuse . COVID-19 and substance use disorder, www.drugabuse.gov/drug-topics/comorbidity/covid-19-substance-use (accessed 10 August 2021).
Google Scholar17. Centers for Disease Control and Prevention. People with certain medical conditions , www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html (accessed 10 August 2021).
Google Scholar18. Khatri, UG, Perrone, J. Opioid use disorder and COVID-19: crashing of the crises [published online ahead of print, 2020 May 12]. J Addict Med 2020; 14: e6–e7.
Google Scholar | Crossref | Medline19. Mukherjee, TI, El-Bassel, N. The perfect storm: COVID-19, mass incarceration and the opioid epidemic. Int J Drug Policy 2020; 83: 102819.
Google Scholar | Crossref | Medline20. Sun, Y, Bao, Y, Kosten, T, et al. Editorial: challenges to opioid use disorders during COVID-19. Am J Addict 2020; 29: 174–175. doi:10.1111/ajad.13031
Google Scholar | Crossref | Medline21. Silva, MJ, Kelly, Z. The escalation of the opioid epidemic due to COVID-19 and resulting lessons about treatment alternatives. Am J Manag Care 2020; 26: e202–e204.
Google Scholar | Crossref | Medline22. Henry, BF, Mandavia, AD, Paschen-Wolff, MM, et al. COVID-19, mental health, and opioid use disorder: old and new public health crises intertwine. Psychol Trauma 2020; 12: S111–S112.
Google Scholar | Crossref | Medline23. Granfield, R, Cloud, W. Coming clean: overcoming addiction without treatment. New York: New York University Press, 1999.
Google Scholar24. Cloud, W, Granfield, R. A life course perspective on exiting addiction: the relevance of recovery capital in treatment. NAD Publication (Nordic Council for Alcohol and Drug Research) 2004; 44: 185–202.
Google Scholar25. National Safety Council. National employer survey 2019: opioid usage in the workplace, www.nsc.org/getmedia/d7221a2a-a6a5-4348-a092-02ed41e9d251/ppw-survey-methodology.pdf (2019, accessed 10 August 2021).
Google Scholar26. National Safety Council . New analysis: employers can save average of $8,500 for supporting each employee in recovery from substance use disorder, www.nsc.org/newsroom/new-analysis-employers-stand-to-save-an-average-of (2 December 2020, accessed 10 August 2021).
Google Scholar27. National Institute for Occupational Safety and Health. About NIOSH , www.cdc.gov/niosh/about/default.html (28 March 2018, accessed 10 August 2021).
Google Scholar28. National Institute for Occupational Safety and Health. Opioids in the workplace: NIOSH confronts the opioid crisis , www.cdc.gov/niosh/topics/opioids/framework.html (15 June 2018, accessed 10 August 2021).
Google Scholar29. National Institute for Occupational Safety and Health. NIOSH Total Worker Health® Program , www.cdc.gov/niosh/twh/default.html (28 July 2020, accessed 10 August 2021).
Google Scholar30. National Institute for Occupational Safety and Health . Using naloxone to reverse opioid overdose in the workplace: information for employers and workers, www.cdc.gov/niosh/docs/2019-101/default.html (5 October 2018, accessed 10 August 2021).
Google Scholar31. National Institute for Occupational Safety and Health. Fentanyl: overview , www.cdc.gov/niosh/topics/fentanyl/default.html (15 November 2016, accessed 10 August 2021).
Google Scholar32. National Institute for Occupational Safety and Health . Fentanyl: preventing emergency responders’ exposures to illicit drugs, www.cdc.gov/niosh/topics/fentanyl/risk.html (11 February 2020, accessed 10 August 2021).
Google Scholar33. National Institute for Occupational Safety and Health . Fentanyl: preventing occupational exposure to healthcare personnel in hospital and clinic settings, www.cdc.gov/niosh/topics/fentanyl/healthcareprevention.html (23 April 2018, accessed 10 August 2021).
Google Scholar34. National Institute for Occupational Safety and Health . Fentanyl: illicit drug tool-kit for first responders, www.cdc.gov/niosh/topics/fentanyl/toolkit.html (5 April 2019, accessed 10 August 2021).
Google Scholar35. National Institute for Occupational Safety and Health. Health hazard evaluations (HHEs) , www.cdc.gov/niosh/hhe/default.html (30 September 2019, accessed 10 August 2021).
Google Scholar36. Howard, J, Cimineri, L, Evans, T, et al. Medication-assisted treatment for opioid use disorder. Washington, DC: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2019-133, 2019. https://doi.org/10.26616/NIOSHPUB2019133
Google Scholar37. Office of National Drug Control Policy, Executive Office of the President . The Biden-Harris administration’s statement of drug policy priorities for year one, www.whitehouse.gov/wp-content/uploads/2021/03/BidenHarris-Statement-of-Drug-Policy-Priorities-April-1.pdf (accessed 10 August 2021).
Google Scholar38. National Institute for Occupational Safety and Health. Workplace supported recovery , www.cdc.gov/niosh/topics/opioids/wsrp/default.html (27 July 2020, accessed 10 August 2021).
Google Scholar39. Alexander, GC, Stoller, KB, Haffajee, RL, et al. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med 2020; 173: 57–58.
Google Scholar | Crossref | Medline